SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane

HER2-positive breast cancer is usually associated to the more aggressive progression and the worse prognosis, but the mechanism underlying the innate resistance to HER2-targeted therapy remains elusive. The sc...

Source: Journal of Experimental and Clinical Cancer Research - May 7, 2020 Category: Cancer & Oncology Authors: Hui Li, Mingming Zhang, Yanli Wei, Farhan Haider, Yitong Lin, Wen Guan, Yanbin Liu, Shaoyang Zhang, Ronghua Yuan, Xia Yang, Shulan Yang and Haihe Wang Tags: Research Source Type: research